Related references
Note: Only part of the references are listed.Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis
Luca Prosperini et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent
Marcus W. Koch et al.
JOURNAL OF NEUROLOGY (2020)
Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis
Carlos Guevara et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Predictive validity of NEDA in the 16-and 21-year follow-up from the pivotal trial of interferon beta-1b
Douglas S. Goodin et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Predictive validity of NEDA in the 16-and 21-year follow-up from the pivotal trial of interferon beta-1b
Douglas S. Goodin et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-la in the EVIDENCE study
Patricia K. Coyle et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years
Fred D. Lublin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Defining Disease Activity and Response to Therapy in MS
Ulrike W. Kaunzner et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Inclusion of brain volume loss in a revised measure of no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Assessing response to interferon-β in a multicenter dataset of patients with MS
Maria Pia Sormani et al.
NEUROLOGY (2016)
Inclusion of brain volume loss in a revised measure of no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Fred D. Lublin et al.
ANNALS OF NEUROLOGY (2013)
Scoring treatment response in patients with relapsing multiple sclerosis
M. P. Sormani et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics
J. W. Lindsey et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2012)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis
C Tortorella et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Share Paper
